E1-INT

an injectable islet neogenesis therapy comprising an epidermal growth factor analog and a gastrin analog, for the treatment of insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetes; Hypoglycemic Agents

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	von Herrath, Matthias: 1 article (10/2005)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 10/01/2005 - "Transition Therapeutics (through its acquisition of Waratah Pharmaceuticals), in collaboration with Novo Nordisk, is developing E1-INT, an injectable islet neogenesis therapy comprising an epidermal growth factor analog and a gastrin analog, for the treatment of insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetes. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Gastrins
3.	Epidermal Growth Factor (EGF)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections